Home › Kanser sa Suso › California › Mountain View
Pag-aaral pangklinika para sa Kanser sa Suso sa Mountain View, CA
26 pag-aaral para sa Kanser sa Suso ang naghahanap ng mga kalahok sa mga site sa loob at paligid ng Mountain View (sa loob ng humigit-kumulang 30 milya). Buksan ang pag-aaral upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.
Opisyal na teksto ng pag-aaral (English)
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
Nagre-recruitPhase 3
- Stanford Women's Cancer Center, Palo Alto · 5 mi ang layo
A Study of PHST001 in Advanced Solid Tumors
Nagre-recruitPhase 1
- Stanford University School of Medicine, Palo Alto · 5 mi ang layo
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
Nagre-recruitPhase 3
- El Camino Hospital, Mountain View
- Palo Alto Medical Foundation, Mountain View
A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer
Nagre-recruitPhase 1/2
- Stanford Medicine Cancer Center, Stanford · 5 mi ang layo
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Nagre-recruitPhase 3
- El Camino Hospital Cancer Center ( Site 0096), Mountain View
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
Nagre-recruitPhase 1
- Stanford University Medical Center, Stanford · 5 mi ang layo
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
Nagre-recruitPhase 1
- Stanford University Medical Center, Stanford · 5 mi ang layo
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Nagre-recruitPhase 3
- Stanford Cancer Center, Palo Alto · 5 mi ang layo
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
Nagre-recruitPhase 3
- Stanford University School of Medicine - Stanford Cancer Institute (SCI) - Stanford Women's Cancer Center, Palo Alto · 5 mi ang layo
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Nagre-recruitPhase 3
- Stanford Women's Cancer Center, Palo Alto · 5 mi ang layo
A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors
Nagre-recruitPhase 1
- Stanford University Hospital, Stanford · 5 mi ang layo
A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer
Nagre-recruitPhase 3
- Research Site, Palo Alto · 5 mi ang layo
A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer
Nagre-recruitPhase 2
- Stanford Cancer Institute, Palo Alto · 5 mi ang layo
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
Nagre-recruitPhase 3
- Palo Alto Medical Foundation Research Center, Palo Alto · 5 mi ang layo
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Nagre-recruitPhase 3
- Palo Alto Medical Foundation-Camino Division, Mountain View
- Palo Alto Medical Foundation-Gynecologic Oncology, Mountain View
- Palo Alto Medical Foundation Health Care, Palo Alto · 5 mi ang layo
- at 1 pa
Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer
Nagre-recruitPhase 2
- Stanford University, Stanford · 5 mi ang layo
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Nagre-recruitPhase 2/3
- Local Institution - 0358, Stanford · 5 mi ang layo
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
Nagre-recruitPhase 3
- Stanford Medicine Cancer Center - Stanford Women's Cancer Center, Palo Alto · 5 mi ang layo
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
Nagre-recruitPhase 1
- Stanford University Medical Center, Palo Alto · 5 mi ang layo
Magnetic Resonance Imaging of Breast Cancer
Nagre-recruitMalugod na tinatanggap ang malusog na boluntaryo
- Stanford University School of Medicine, Stanford · 5 mi ang layo
Genetic & Pathological Studies of BRCA1/BRCA2: Associated Tumors & Blood Samples
Nagre-recruitObservasyonal na pag-aaral
- Stanford University School of Medicine, Stanford · 5 mi ang layo
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
Nagre-recruitPhase 3
- Palo Alto Medical Foundation-Camino Division, Mountain View
- Palo Alto Medical Foundation Health Care, Palo Alto · 5 mi ang layo
- Stanford Cancer Institute Palo Alto, Palo Alto · 5 mi ang layo
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Nagre-recruitPhase 1
- Stanford Cancer Institute, Stanford · 5 mi ang layo
Surgical Excision vs Neoadjuvant Radiotherapy+Delayed Surgical Excision of Ductal Carcinoma
Nagre-recruit
- Stanford University, Stanford · 5 mi ang layo
EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)
Nagre-recruitObservasyonal na pag-aaral
- Stanford Cancer Institute, Palo Alto · 5 mi ang layo
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Nagre-recruitObservasyonal na pag-aaral
- Massive Bio SYNERGY-AI site, Stanford · 5 mi ang layo
Pag-aaral para sa Kanser sa Suso sa ibang lungsod
- New York City, NY136 pag-aaral
- Houston, TX126 pag-aaral
- Boston, MA112 pag-aaral
- Nashville, TN81 pag-aaral
- Los Angeles, CA73 pag-aaral
- Edison, NJ68 pag-aaral
- St. Louis, MO64 pag-aaral
- Queens, NY64 pag-aaral
- Durham, NC64 pag-aaral
- Chicago, IL59 pag-aaral
- Philadelphia, PA56 pag-aaral
- Dallas, TX55 pag-aaral
Iba pang pag-aaral sa Mountain View
- Kanser (lahat ng uri)40 pag-aaral
- Metastatic Cancer25 pag-aaral
- Non-Small Cell Lung Cancer21 pag-aaral
- Acute Myeloid Leukemia19 pag-aaral
- Kanser sa Ovary19 pag-aaral
- Autism Spectrum Disorder17 pag-aaral
- Kanser sa Baga17 pag-aaral
- Kanser sa Prostate15 pag-aaral
- Pagkabigo ng Puso15 pag-aaral
- Autism13 pag-aaral
- Acute Lymphoblastic Leukemia13 pag-aaral
- Colorectal Cancer13 pag-aaral
Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.